Worth reading
58In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
8.2
% (year-on-year change in consolidated revenue)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales257,967¥ millionYear on year +8.2%Progress 80.9%
Operating profit47,411¥ millionYear on year +4.6%Progress 94.8%
Ordinary income50,366¥ millionYear on year +8.1%Progress 98.8%
Net income attributable to owners of the parent40,550¥ millionYear on year +11.1%Progress 104.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥176.34
Operating Margin18.4% (19.0% in the previous fiscal year)
Financial position at period-end
Total assets399,168¥ million
of which net assets 296,465 ¥ millionEquity ratio 74.0%vs. prior year-end -4.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+35,865
Investment-4,427
Financials-31,407
Net change+31
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥82,973 million
Segment revenueFunctional Chemicals business ¥145,751 million (YoY -3.4%), Pharmaceuticals, Medical Care and Healthcare Business ¥49,931 million (YoY +4.0%), Industrial Explosives Business ¥61,675 million (YoY +59.1%)
Segment profitFunctional Chemicals business ¥26,846 million (YoY -9.9%), Pharmaceuticals, Medical Care and Healthcare Business ¥15,816 million (YoY +0.8%), Industrial Explosives Business ¥7,979 million (YoY +154.9%)
Regional sales¥186,271 million, ¥37,168 million, ¥17,212 million, ¥17,314 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥319,000 million (YoY +23.7%)
Operating profit¥50,000 million (YoY +5.5%)
Ordinary income¥51,000 million (YoY +1.3%)
Net income¥39,000 million (YoY -3.8%)
Annual Dividend Forecast¥45 → ¥70（+55.6%）
Payout ratio34.6% (FY2026 March), 41.3% (FY2027 March forecast)
Shareholder Return PolicySet a total payout ratio of approximately 50% as the target level for the final year of the medium-term management plan
Factors Behind Changes in Business Performance
The company worked to develop new markets and expand sales, while reducing production costs. The Functional Chemicals Business reported lower net sales and profit amid sluggish demand. The Pharmaceuticals, Medical Care and Healthcare Business reported higher net sales and profit, supported by increased shipments for use in health foods and other factors. The Industrial Explosives Business achieved substantial increases in net sales and profit, driven by increased shipments of rocket-related products and the recognition of revenue from certain transactions related to early deployment.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNewly included: — company; excluded: — company
Material subsequent eventsAt a meeting of the Board of Directors held on 11 May 2026, the company resolved to acquire treasury shares. The acquisition will cover up to 1.7 million shares, with a maximum total acquisition price of ¥5 billion, during the period from 12 May to 30 June 2026.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥7 million, Gain on sale of investment securities ¥8,770 million, Gain on revision of retirement benefit plans ¥58 million, Other ¥4 million / Extraordinary loss Loss on sale of fixed assets ¥6 million, Loss on Disposal of Fixed Assets ¥230 million, Valuation loss on investments in affiliates ¥1,639 million
Depreciation and amortization¥22,116 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End236,524,128 Shares
Treasury Shares at Period-End10,089,463 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥257,967 million (YoY +8.2%) |
| Operating profit | ¥47,411 million (YoY +4.6%) |
| Ordinary income | ¥50,366 million (YoY +8.1%) |
| Profit attributable to owners of the parent | ¥40,550 million (YoY +11.1%) |
| Net income per share | ¥176.34 |
| Operating Margin | 18.4% (19.0% in the previous fiscal year) |
| Equity ratio | End of the current fiscal period 74 / End of previous period 78 |
| Total assets | ¥399,168 million |
| Net assets | ¥296,465 million |
| Cash flows from operating activities | ¥35,865 million |
| Cash flows from investing activities | ¥-4,427 million |
| Cash flows from financing activities | ¥-31,407 million |
| Cash and cash equivalents at end of period | ¥82,973 million |
| Full-year earnings forecast | Net Sales ¥319,000 million (YoY +23.7%) / Operating profit ¥50,000 million (YoY +5.5%) / Ordinary income ¥51,000 million (YoY +1.3%) / Net income ¥39,000 million (YoY -3.8%) |
| Annual Dividend Forecast | ¥45 → ¥70（+55.6%） |
| Payout ratio | 34.6% (FY2026 March), 41.3% (FY2027 March forecast) |
| Shareholder Return Policy | Set a total payout ratio of approximately 50% as the target level for the final year of the medium-term management plan |
| Segment revenue | Functional Chemicals business ¥145,751 million (YoY -3.4%), Pharmaceuticals, Medical Care and Healthcare Business ¥49,931 million (YoY +4.0%), Industrial Explosives Business ¥61,675 million (YoY +59.1%) |
| Segment profit | Functional Chemicals business ¥26,846 million (YoY -9.9%), Pharmaceuticals, Medical Care and Healthcare Business ¥15,816 million (YoY +0.8%), Industrial Explosives Business ¥7,979 million (YoY +154.9%) |
| Regional sales | ¥186,271 million, ¥37,168 million, ¥17,212 million, ¥17,314 million |
| Depreciation and amortization | ¥22,116 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥7 million, Gain on sale of investment securities ¥8,770 million, Gain on revision of retirement benefit plans ¥58 million, Other ¥4 million / Extraordinary loss Loss on sale of fixed assets ¥6 million, Loss on Disposal of Fixed Assets ¥230 million, Valuation loss on investments in affiliates ¥1,639 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Newly included: — company; excluded: — company |
| Material subsequent events | At a meeting of the Board of Directors held on 11 May 2026, the company resolved to acquire treasury shares. The acquisition will cover up to 1.7 million shares, with a maximum total acquisition price of ¥5 billion, during the period from 12 May to 30 June 2026. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 236,524,128 Shares |
| Treasury Shares at Period-End | 10,089,463 Shares |
| Factors Behind Changes in Business Performance | The company worked to develop new markets and expand sales, while reducing production costs. The Functional Chemicals Business reported lower net sales and profit amid sluggish demand. The Pharmaceuticals, Medical Care and Healthcare Business reported higher net sales and profit, supported by increased shipments for use in health foods and other factors. The Industrial Explosives Business achieved substantial increases in net sales and profit, driven by increased shipments of rocket-related products and the recognition of revenue from certain transactions related to early deployment. |
Items this document does not state (3)
Revision to Earnings ForecastOrders received and order backlogImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company worked to develop new markets and expand sales, while reducing production costs. In the industrial explosives business, increased shipments of rocket-related products and the recognition of revenue from certain transactions involving initial costs for the early deployment of defense-related products contributed to higher net sales and profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.